Biological sample export restrictions during pandemics

1. Introduction

Biological sample export restrictions during pandemics refer to the legal and regulatory measures imposed by governments to control or restrict the international transfer of biological materials during public health emergencies. These materials may include human blood, tissue samples, respiratory specimens, viral isolates, bacterial cultures, genetic material, and other biological substances collected for medical research, diagnostic testing, vaccine development, and pharmaceutical production.

During pandemics, biological samples become particularly important because they help scientists identify infectious agents, understand disease transmission, develop diagnostic tests, and manufacture vaccines and medicines. However, unrestricted international movement of biological materials may create risks relating to biosafety, biosecurity, national sovereignty, public health protection, and equitable access to scientific benefits.

Governments may therefore introduce export restrictions, licensing requirements, special permissions, quarantine procedures, and documentation obligations. Such measures attempt to balance national public health interests with international scientific cooperation.

The regulation of biological sample exports also raises questions concerning ownership of biological materials, genetic information, intellectual property, benefit-sharing, and the rights of individuals who provide samples.

2. Meaning and Objectives of Biological Sample Export Restrictions

Biological sample export restrictions are legal controls imposed on the transfer of biological materials from one country to another.

These restrictions may apply to infectious disease specimens, human biological samples, pathogenic microorganisms, genetic resources, and other materials requiring special regulatory supervision.

Their major objectives include:

Preventing the uncontrolled international movement of infectious biological materials.

Protecting national public health and biological security.

Ensuring compliance with biosafety and biosecurity requirements.

Preventing unauthorised commercial exploitation of biological resources.

Protecting the privacy and rights of biological sample donors.

Ensuring fair and equitable sharing of research benefits.

Maintaining national control over strategically important biological materials.

For example, during an influenza pandemic, a government may require special authorisation before infectious viral samples can be exported to an overseas research institution. Such authorisation may ensure that the receiving laboratory has appropriate containment facilities and that the transfer serves legitimate scientific or public health purposes.

3. Types of Biological Samples Subject to Export Restrictions

Different categories of biological materials may be subject to different legal requirements.

A. Human Biological Samples

These include:

Blood and plasma.

Human tissue specimens.

Respiratory samples.

Bone marrow samples.

Human cells and cell lines.

DNA and RNA extracts.

Export may require compliance with human-subject research ethics, donor consent, privacy requirements, and applicable national regulations.

B. Pathogenic Microorganisms

These include viruses, bacteria, fungi, and other biological agents capable of causing disease.

During pandemics, governments may apply stricter controls to infectious samples because their international movement may create biosafety and biosecurity concerns.

C. Genetic and Genomic Materials

Genetic materials may be exported for sequencing, genomic analysis, vaccine research, and biotechnology development.

Such transfers may raise questions concerning genetic privacy, ownership, intellectual property, and access and benefit-sharing obligations.

D. Animal and Plant Biological Samples

Animal and plant specimens may also be subject to export restrictions, particularly where they contain infectious organisms or constitute regulated genetic resources.

4. International Legal Framework Governing Biological Sample Exports

A. International Health Regulations (2005)

The International Health Regulations (IHR 2005), adopted under the World Health Organization framework, establish international obligations concerning the prevention and control of public health risks.

Article 2 establishes the purpose of preventing, protecting against, controlling, and providing a public health response to the international spread of disease while avoiding unnecessary interference with international traffic and trade.

Article 43 permits States Parties to implement additional health measures where justified by public health risks, subject to specified conditions.

However, such measures must be based on scientific principles and available scientific evidence and should not be more restrictive of international traffic than reasonably available alternatives.

The IHR also provides a framework for international public health cooperation and information exchange.

B. Convention on Biological Diversity, 1992

The Convention on Biological Diversity recognises the sovereign rights of countries over their natural resources.

Article 15 establishes principles governing access to genetic resources and fair and equitable sharing of benefits.

These principles may become relevant when exported biological samples contain genetic resources covered by the Convention and applicable domestic access and benefit-sharing laws.

C. Nagoya Protocol, 2010

The Nagoya Protocol establishes an international framework for access to genetic resources and benefit-sharing.

It is particularly relevant to biological samples collected from plants, animals, and microorganisms for biotechnology and pharmaceutical research.

Its provisions address prior informed consent, mutually agreed terms, and compliance with domestic access and benefit-sharing legislation.

However, the Protocol does not automatically impose identical export restrictions on every human biological sample or pandemic specimen.

D. Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES), 1973

CITES regulates international trade in specimens of listed endangered species.

Where biological samples originate from species covered by CITES, relevant export permits and certificates may be required.

This framework is particularly relevant when pandemic research involves wildlife-derived biological specimens.

E. Biological Weapons Convention, 1972

The Biological Weapons Convention prohibits the development, production, stockpiling, and acquisition of biological agents and toxins for prohibited purposes.

It is relevant to the international control of certain biological materials and supports broader biosafety and biosecurity objectives.

5. Biological Sample Export Restrictions During COVID-19

The COVID-19 pandemic demonstrated the importance of regulating international biological sample transfers.

Researchers required access to SARS-CoV-2 samples and genetic sequence information to develop diagnostic tests, vaccines, and treatments.

However, international transfers raised several regulatory questions:

A. Export Authorisation

Countries could apply national export-control requirements to specified biological materials, depending on their legal classification and applicable emergency measures.

B. Biosafety Requirements

Laboratories receiving infectious specimens were expected to follow appropriate biosafety standards, including relevant containment and transportation requirements.

C. International Research Cooperation

Scientific institutions required mechanisms to exchange samples and research information across national borders.

D. Equitable Access

Developing countries raised concerns about providing biological samples and genetic information without receiving fair access to vaccines, diagnostics, and resulting scientific benefits.

The COVID-19 experience highlighted the importance of balancing national regulatory control with international public health cooperation.

6. Biological Sample Export Regulation in India

India regulates biological sample exports through multiple legal and administrative frameworks, depending on the type of material, its intended use, and its potential hazards.

A. Foreign Trade (Development and Regulation) Act, 1992

The Foreign Trade (Development and Regulation) Act, 1992, provides the legal framework for regulating imports and exports in India.

The Directorate General of Foreign Trade (DGFT) administers India's export policy through the Foreign Trade Policy and applicable notifications.

Specified biological materials may require export authorisation or may be subject to restrictions under the relevant export policy classification.

B. Biological Diversity Act, 2002

The Biological Diversity Act, 2002, as amended in 2023, regulates access to biological resources and associated traditional knowledge.

The National Biodiversity Authority (NBA) plays an important role in regulating relevant activities involving biological resources.

Where exported samples fall within the Act's scope, applicable access, approval, and benefit-sharing requirements must be considered.

C. Environment (Protection) Act, 1986

The Environment (Protection) Act, 1986, provides the statutory foundation for regulating environmentally hazardous activities.

Rules concerning hazardous substances and biological waste may become relevant where the transportation or handling of biological materials creates environmental risks.

D. Epidemic Diseases Act, 1897

The Epidemic Diseases Act, 1897, empowers governments to adopt special measures and regulations for preventing the spread of dangerous epidemic diseases.

During public health emergencies, authorities may introduce additional controls relevant to the handling and movement of biological materials, subject to applicable legal authority.

E. Biomedical Waste Management Rules, 2016

These rules regulate the handling, collection, storage, transportation, treatment, and disposal of biomedical waste.

They are relevant to biological specimens that become biomedical waste, although they should not be confused with a general export-licensing framework for research samples.

7. Important Case Laws and Judicial Developments

There are limited reported judicial decisions directly addressing biological sample export restrictions during pandemics. However, several important judgments establish principles concerning public health regulation, biological resources, privacy, international trade, and environmental protection.

A. Jacobson v. Massachusetts (1905)

Citation: 197 U.S. 11 (1905).

The United States Supreme Court examined the constitutional validity of compulsory vaccination requirements introduced to protect public health during a smallpox outbreak.

The Court recognised the authority of governments to adopt reasonable public health measures to protect communities.

Relevance: The judgment establishes the broader principle that individual interests and commercial activities may be subject to reasonable public health regulation. Similar principles may support justified restrictions on the international movement of infectious biological samples.

B. Gibbons v. Ogden (1824)

Citation: 22 U.S. (9 Wheat.) 1 (1824).

The United States Supreme Court interpreted the constitutional power of Congress to regulate interstate commerce.

The judgment established important principles concerning governmental authority over commercial movement.

Relevance: Although the case concerned interstate commerce rather than biological materials, it provides a broader constitutional background for understanding the relationship between trade regulation and governmental authority.

C. S. Jagannath v. Union of India (1997)

Citation: (1997) 2 SCC 87.

The Supreme Court of India considered environmental damage caused by intensive shrimp aquaculture activities.

The Court applied environmental protection principles and emphasised the importance of sustainable development.

Relevance: The decision is relevant where the collection, transportation, or commercial utilisation of biological resources creates environmental risks. It supports regulatory oversight of activities affecting ecological resources.

D. K.S. Puttaswamy v. Union of India (2017)

Citation: (2017) 10 SCC 1.

The Supreme Court of India recognised privacy as a fundamental right under the Constitution.

The judgment explained that privacy includes personal autonomy, dignity, and protection of personal information.

Relevance: Human biological samples may contain sensitive genetic and medical information. Their international transfer for research purposes must therefore consider privacy, consent, confidentiality, and appropriate data protection.

E. Divya Pharmacy v. Union of India (2018)

Citation: Uttarakhand High Court, Writ Petition (M/S) No. 3437 of 2016, decided on 21 December 2018.

The case examined the applicability of benefit-sharing obligations under the Biological Diversity Act, 2002, to domestic commercial entities using biological resources.

The High Court upheld the statutory benefit-sharing framework in the circumstances before it.

Relevance: The decision is important when exported biological samples contain genetic resources subject to biodiversity legislation. It demonstrates that commercial utilisation of biological resources may attract benefit-sharing responsibilities.

F. WTO Appellate Body Report, Brazil – Measures Affecting Imports of Retreaded Tyres (2007)

Citation: WT/DS332/AB/R.

The WTO Appellate Body examined Brazil's restrictions on imports of retreaded tyres and considered the relationship between trade restrictions and environmental and public health protection.

It recognised that trade-restrictive measures may be justified under applicable WTO exceptions, subject to the relevant legal conditions.

Relevance: The decision provides an important international trade principle: restrictions on international trade for legitimate public health or environmental objectives must satisfy applicable legal requirements and cannot be arbitrary or unjustifiably discriminatory.

8. Regulatory Challenges in Biological Sample Export Restrictions

Biological sample export restrictions create several scientific, legal, and administrative challenges.

A. Conflict Between National Sovereignty and Scientific Cooperation: Countries may seek to retain control over biological resources, while international researchers require timely access to samples for disease surveillance and vaccine development.

B. Delays in Emergency Research: Excessive authorisation requirements may delay the exchange of biological specimens during rapidly developing outbreaks.

C. Unclear Ownership Rights: Legal ownership and control over biological samples may involve donors, hospitals, research institutions, governments, and commercial organisations.

D. Intellectual Property Disputes: Companies may develop commercially valuable technologies using exported biological materials, raising questions concerning ownership and benefit-sharing.

E. Biosafety and Biosecurity Risks: Infectious materials require suitable packaging, transportation, laboratory safeguards, and risk assessments.

F. Inequality Between Countries: Developing countries may contribute biological materials to international research without receiving proportionate access to resulting vaccines, medicines, or diagnostic technologies.

G. Different National Regulations: Countries may apply different export-control systems, creating compliance difficulties for multinational research projects.

9. Conclusion

Biological sample export restrictions during pandemics are an important component of international public health law, biotechnology regulation, and biological security. They seek to protect national populations, prevent the uncontrolled movement of infectious materials, preserve biological resources, and ensure responsible scientific research.

The International Health Regulations (2005), Convention on Biological Diversity, Nagoya Protocol, Biological Weapons Convention, and applicable national export-control legislation provide important regulatory foundations.

In India, the Foreign Trade (Development and Regulation) Act, 1992, Biological Diversity Act, 2002, Epidemic Diseases Act, 1897, and Biomedical Waste Management Rules, 2016, may apply depending on the nature and purpose of the biological material.

Judicial decisions such as Jacobson v. Massachusetts, K.S. Puttaswamy v. Union of India, and Divya Pharmacy v. Union of India establish relevant principles concerning public health protection, genetic privacy, and equitable benefit-sharing.

Ultimately, an effective regulatory framework must balance national sovereignty, public health security, scientific cooperation, individual privacy, and equitable access to the benefits of biomedical research. Properly designed export restrictions can protect communities without unnecessarily obstructing international collaboration during global health emergencies.